New drug combo before liver surgery shows promise in early trial
NCT ID NCT04721132
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to see how many patients have no cancer cells left in the removed tumor and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs given intravenously)
- What this could lead to
- If it works, this approach could reduce the chance of liver cancer coming back after surgery, potentially improving long-term outcomes.
- What could go wrong
- This is a small, early-phase trial with only 16 participants, so results may not apply broadly. The combination can cause immune-related side effects and bleeding risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple immunotherapy cocktail aims to boost surgery success in liver cancer
- Drug cocktail aims to stop liver cancer recurrence after surgery
- New blood test aims to catch liver cancer recurrence early
- New drug combo shows promise in shrinking liver tumors before surgery
- New drug combo aims to shrink liver tumors before surgery
- Proton beam therapy tested for liver cancer – early results show promise and risks